IP Verse

Anti-Pd-L1 Combinations For Treating Tumors - EP3166976

The patent EP3166976 was granted to Birdie Biopharmaceuticals on Feb 23, 2022. The application was originally filed on Jul 8, 2015 under application number EP15819519A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3166976

BIRDIE BIOPHARMACEUTICALS
Application Number
EP15819519A
Filing Date
Jul 8, 2015
Status
Granted And Under Opposition
Jan 21, 2022
Grant Date
Feb 23, 2022
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PATENT BOUTIQUENov 23, 2022-WITHDRAWN

Patent Citations (115) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0404097
DESCRIPTIONUS2002064780
DESCRIPTIONUS2003054360
DESCRIPTIONUS2003087301
DESCRIPTIONUS2003175950
DESCRIPTIONUS2004014779
DESCRIPTIONUS2004043923
DESCRIPTIONUS2004072234
DESCRIPTIONUS2004092470
DESCRIPTIONUS2004162309
DESCRIPTIONUS2004192626
DESCRIPTIONUS2005020525
DESCRIPTIONUS2005032733
DESCRIPTIONUS2005069910
DESCRIPTIONUS2007202100
DESCRIPTIONUS2008025980
DESCRIPTIONUS2008311117
DESCRIPTIONUS2009110667
DESCRIPTIONUS2010143301
DESCRIPTIONUS2012149061
DESCRIPTIONUS2012237977
DESCRIPTIONUS2013022595
DESCRIPTIONUS2013150558
DESCRIPTIONUS2014044738
DESCRIPTIONUS2014088085
DESCRIPTIONUS4689338
DESCRIPTIONUS5226575
DESCRIPTIONUS5229275
DESCRIPTIONUS5270163
DESCRIPTIONUS5352784
DESCRIPTIONUS5389640
DESCRIPTIONUS5482936
DESCRIPTIONUS5567588
DESCRIPTIONUS5567610
DESCRIPTIONUS5571894
DESCRIPTIONUS5587458
DESCRIPTIONUS5595877
DESCRIPTIONUS5660985
DESCRIPTIONUS5696249
DESCRIPTIONUS5763177
DESCRIPTIONUS5789163
DESCRIPTIONUS5817785
DESCRIPTIONUS5843653
DESCRIPTIONUS5843732
DESCRIPTIONUS5853984
DESCRIPTIONUS5869046
DESCRIPTIONUS5874218
DESCRIPTIONUS5958691
DESCRIPTIONUS5977089
DESCRIPTIONUS6001577
DESCRIPTIONUS6005087
DESCRIPTIONUS6031086
DESCRIPTIONUS6110929
DESCRIPTIONUS6127533
DESCRIPTIONUS6184364
DESCRIPTIONUS6194425
DESCRIPTIONUS6225460
DESCRIPTIONUS6242246
DESCRIPTIONUS6248516
DESCRIPTIONUS6331539
DESCRIPTIONUS6344318
DESCRIPTIONUS6376190
DESCRIPTIONUS6399754
DESCRIPTIONUS6403779
DESCRIPTIONUS6451810
DESCRIPTIONUS6458539
DESCRIPTIONUS6458543
DESCRIPTIONUS6465189
DESCRIPTIONUS6482594
DESCRIPTIONUS6716583
DESCRIPTIONUS6803192
DESCRIPTIONUS6808710
DESCRIPTIONUS6924271
DESCRIPTIONUS7101550
DESCRIPTIONUS7105328
DESCRIPTIONUS7488802
DESCRIPTIONUS7576068
DESCRIPTIONUS7635757
DESCRIPTIONUS7722868
DESCRIPTIONUS7943743
DESCRIPTIONUS8008449
DESCRIPTIONUS8138172
DESCRIPTIONUS8168757
DESCRIPTIONUS8246968
DESCRIPTIONUS8354509
DESCRIPTIONUS8513390
DESCRIPTIONUS8518404
DESCRIPTIONUS8552154
DESCRIPTIONUS8575180
DESCRIPTIONUS8779108
DESCRIPTIONWO0114557
DESCRIPTIONWO02100442
DESCRIPTIONWO0246192
DESCRIPTIONWO0246193
DESCRIPTIONWO0246194
DESCRIPTIONWO2004056875
DESCRIPTIONWO2006117217
DESCRIPTIONWO2007024612
DESCRIPTIONWO2007040840
DESCRIPTIONWO2008004948
DESCRIPTIONWO2011066389
DESCRIPTIONWO2013043647
DESCRIPTIONWO2013079174
DESCRIPTIONWO2014012479
DESCRIPTIONWO9301161
DESCRIPTIONWO9316185
DESCRIPTIONWO9808856
EXAMINATIONUS2017114137
INTERNATIONAL-SEARCH-REPORTUS2014012479
INTERNATIONAL-SEARCH-REPORTWO2014012479
OPPOSITIONUS2002015715
OPPOSITIONUS2017114137
OPPOSITIONWO2013043647
OPPOSITIONWO2014012479
SEARCHWO2013043647

Non-Patent Literature (NPL) Citations (91) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- AGATA, T. et al., Int. Immunol., (19960000), vol. 8, no. 5, pages 765 - 772
DESCRIPTION- BELL DCHOMARAT PBROYLES D et al., "In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas", J Exp Med, (19990000), vol. 190, pages 1417 - 1425
DESCRIPTION- BERGER et al., Clin Cancer Res, (20080000), vol. 14, pages 13044 - 51
DESCRIPTION- BLANK, C. et al., Immunol. Immunother., (20061229), vol. 56, no. 5, pages 739 - 745
DESCRIPTION- BRAHMER et al., N Eng J Med, (20120000), vol. 366, pages 2455 - 65
DESCRIPTION- BRAHMER et al., N Eng J Med, vol. 366, pages 2455 - 65
DESCRIPTION- BUTTE et al., Immunity, (20070000), vol. 27, page 111
DESCRIPTION- CHERFILS-VICINI JPLATONOVA SGILLARD MLAURANS LVALIDIRE PCALIANDRO RMAGDELEINAT PMAMI-CHOUAIB FDIEU-NOSJEAN MCFRIDMAN WH, J. Clin Invest., (20100000), vol. 120, no. 4, pages 1285 - 1297
DESCRIPTION- CHOTHIA et al., J Mol Biol, (19870000), vol. 196, pages 901 - 917
DESCRIPTION- DUMMER RUROSEVIC MKEMPF W et al., "Imiquimod in basal cell carcinoma: how does it work?", Br J Dermatol, (20030000), vol. 149, pages 57 - 58
DESCRIPTION- GABRILOVICH DICORAK JCIERNIK IF et al., "Decreased antigen presentation by dendritic cells in patients with breast cancer", Clin Cancer Res, (19970000), vol. 3, pages 483 - 490
DESCRIPTION- GREEN et al., Nature Genet, (19940000), vol. 113, pages 269 - 315
DESCRIPTION- HARTMANN EWOLLENBERG BROTHENFUSSER S et al., "Identification and functional analysis of tumor-infiltrating plasmacytoid dendritic cells in head and neck cancer", Cancer Res, (20030000), vol. 63, pages 6478 - 6487
DESCRIPTION- HEELEY, Endocr Res, (20020000), vol. 28, pages 217 - 229
DESCRIPTION- HOLLINGER et al., Proc Natl Acad Sci USA, (19930000), vol. 90, pages 6444 - 6448
DESCRIPTION- HUANG B et al., "Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling", Cancer Res, (20070000), vol. 67, no. 9, pages 4346 - 4352
DESCRIPTION- HUANG B et al., "Toll-like receptors on tumor cells facilitate evasion of immune surveillance", Cancer Res., (20050000), vol. 65, no. 12, pages 5009 - 5014
DESCRIPTION- HUDSON et al., Nat Med, (20030000), vol. 9, pages 129 - 134
DESCRIPTION- ISHIDA, Y. et al., EMBO J, (19920000), vol. 11, pages 3887 - 3895
DESCRIPTION- JOHNSONCHISWELL, Current Opinion in Structural Biology, (19930000), vol. 3, pages 5564 - 571
DESCRIPTION- JURK et al., Nature Immunology, (20020000), vol. 4, no. 6, page 499
DESCRIPTION- LILJEBLAD et al., Glyco J, (20000000), vol. 17, pages 323 - 329
DESCRIPTION- LIN et al., J. Am. Chem. Soc., (20050000), vol. 17, page 4570
DESCRIPTION- LONBERG et al., Nature, (19940000), vol. 368, page 856
DESCRIPTION- LOWDELL et al., Bone Marrow Transplant, (19980000), vol. 21, pages 679 - 686
DESCRIPTION- LOWDELL, Transfusion Medicine, (20030000), vol. 13, pages 399 - 404
DESCRIPTION- MARTIN-OROZCO, N. et al., Semin. Cancer Biol., (20070000), vol. 17, no. 4, pages 288 - 298
DESCRIPTION- MATHIOWITZ et al., J. Appl. Polymer Sci., (19880000), vol. 35, page 755
DESCRIPTION- MATHIOWITZ et al., J. Control. Release, (19870000), vol. 5, page 13
DESCRIPTION- MATHIOWITZ et al., Reactive Polymers, (19870000), vol. δ, page 275
DESCRIPTION- MCCAFFERTY et al., Nature, (19900000), vol. 348, pages 1289 - 1329
DESCRIPTION- MENETRIER-CAUX CMONTMAIN GDIEU MC et al., "Inhibition of the differentiation of dendritic cells from CD34 (+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor", Blood, (19980000), vol. 92, pages 4778 - 4791, XP002165345
DESCRIPTION- MENZIESLONG, Ther Adv Med Oncol, (20130000), vol. 5, pages 278 - 85
DESCRIPTION- MURRAY et al., Ann. Rev. Mat. Sci., (20000000), vol. 30, page 545
DESCRIPTION- NISHIMURA, H. et al., J. Exp. Med., (20000000), vol. 192, pages 1027 - 898
DESCRIPTION- "Oligonucleotide synthesis: methods and applications", Methods in molecular biology, Humana Press, (20050000), vol. 288
DESCRIPTION- PELLEGRINO et al., Small, (20050000), vol. 1, page 48
DESCRIPTION- POCKROS et al., J. Hepatology, (20070000), vol. 47, pages 174 - 182
DESCRIPTION- PRIBBLE PEDELMAN MJ, "EC145: a novel targeted agent for adenocarcinoma of the lung", Expert Opin. Investig. Drugs, (20120000), vol. 21, pages 755 - 761
DESCRIPTION- RADVANYI et al., Clin Cancer Res, (20130000), vol. 19, pages 5541 - 9
DESCRIPTION- REITTIE et al., Blood, (19890000), vol. 73, pages 1351 - 1358
DESCRIPTION- SALAUN BCOSTE IRISSOAN MCLEBECQUE SJRENNO T, "TLR3 can directly trigger apoptosis in human cancer cells", J Immunol., (20060000), vol. 176, no. 8, pages 4894 - 4901
DESCRIPTION- STEINMAN et al., J. Exp. Med., (19790000), vol. 149, pages 1 - 16
DESCRIPTION- SUBUDHI et al., J. Clin. Invest., (20040000), vol. 113, page 694
DESCRIPTION- TAMURA et al., Blood, (20010000), vol. 97, page 1809
DESCRIPTION- TAYLOR et al., Int. Immun., (19940000), vol. 6, page 579
DESCRIPTION- TOPALIAN et al., N Engl J Med, (20120000), vol. 366, pages 2443 - 54
DESCRIPTION- TREILLEUX IBLAY JYBENDRISS-VERMARE N et al., "Dendritic cell infiltration and prognosis of early stage breast cancer", Clin Cancer Res, (20040000), vol. 10, pages 7466 - 7474
DESCRIPTION- TRINDADE et al., Chem. Mat., (20010000), vol. 13, page 3843
DESCRIPTION- XIA WLOW PS, "Late-targeted therapies for cancer", J Med Chem., (20100000), vol. 53, no. 19, pages 6811 - 24
DESCRIPTION- YAMAZAKI, T. et al., J. Immunol., (20020000), vol. 169, pages 5538 - 5545
DESCRIPTION- ZOU WPMACHELON VCOULOMB-L'HERMIN A et al., "Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells", Nat Med, (20010000), vol. 7, pages 1339 - 1346
DESCRIPTION- HE WLIU QWANG LCHEN WLI NCAO X, "TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance", Mol Immunol, (20070000), vol. 44, no. 11, doi:10.1016/j.molimm.2007.01.022, pages 2850 - 2859, XP005938369
DESCRIPTION- MILLER RLGERSTER JFOWENS ML et al., "Imiquimod applied topically: a novel immune response modifier and new class of drug", Int J Immunopharmacol, (19990000), vol. 21, doi:10.1016/S0192-0561(98)00068-X, pages 1 - 14, XP000900725
DESCRIPTION- SCOTT AMWOLCHOK JDOLD LJ, "Antibody therapy of cancer", Nat Rev Cancer, (20120000), vol. 12, no. 4, doi:10.1038/nrc3236, pages 278 - 87, XP055531673
DESCRIPTION- GILLIET MCAO WLIU YJ, "Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases", Nat Rev Immunol, (20080800), vol. 8, no. 8, doi:10.1038/nri2358, pages 594 - 606, XP055548464
DESCRIPTION- HOFMANN MAKORS CAUDRING H et al., "Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma", J Immunother, (20080000), vol. 31, doi:10.1097/CJI.0b013e318174a4df, pages 520 - 527, XP009500479
DESCRIPTION- LIU YJ, "IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors", Annu Rev Immunol, (20050000), vol. 23, doi:10.1146/annurev.immunol.23.021704.115633, pages 275 - 306, XP002344020
DESCRIPTION- DROEMANN D et al., "Human lung cancer cells express functionally active Toll-like receptor 9", Respir Res, (20050000), vol. 6, doi:10.1186/1465-9921-6-1, page 1, XP021000041
OPPOSITION- EMA Glossary
OPPOSITION- Goldstein et al
OPPOSITION- Ilyinskii et al., 2014
OPPOSITION- Prodeus et al
OPPOSITION- WEBSTER et al., "Targeting Molecular and Cellular Inhibitory Mechanisms for Improvement of Antitumor Memory Responses Reactivated by Tumor Cell", Vaccine, J. Immunol., (20070901), vol. 179, pages 2860 - 2869, XP002557388
OPPOSITION- York A.
OPPOSITION- WÖLFLE et al., "PD-L1 expression on tolerogenic APCs is controlled by STAT-3", Eur. J. Immunol., (20101208), vol. 41, doi:10.1002/eji.201040979, pages 413 - 424, XP055448458
OPPOSITION- Hornung V, Barchet W, Schlee M, Hartmann G, "RNA Recognition via TLR7 and TLR8", Toll-Like Receptors (TLRs) and Innate Immunity / HANDBOOK OF EXPERIMENTAL PHARMACOLOGY, (20080101), vol. 183, pages 71 - 86, doi:10.1007/978-3-540-72167-3_4, XP009131361
OPPOSITION- Shaherin Basith et al, "Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense", Archives of Pharmacal Research, Pharmaceutical Society of Korea, Heidelberg, Heidelberg , (20120901), vol. 35, no. 8, doi:10.1007/s12272-012-0802-7, ISSN 1976-3786, pages 1297 - 1316, XP035106358
OPPOSITION- TOPALIAN et al., "Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity", Current Opinion in Immunology, (20120000), vol. 24, doi:10.1016/j.coi.2011.12.009, pages 207 - 212, XP002714810
OPPOSITION- POCKROS et al., "Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo- controlled, double-blind phase IIa studies", Journal of Hepatology, (20070504), vol. 47, no. 2, doi:10.1016/j.jhep.2007.02.025, pages 174 - 182, XP022144534
OPPOSITION- SMIRNOV et al., "Vaccine adjuvant activity of 3M- 052: an imidazoquinoline designed for local activity without systemic cytokine induction", Vaccine, (20110726), vol. 29, doi:10.1016/j.vaccine.2011.05.061, pages 5434 - 5442, XP028240658
OPPOSITION- Eager, R. Nemunaitis, J., "GM-CSF Gene-Transduced Tumor Vaccines", Molecular Therapy, Elsevier Inc, United States, United States, (20050701), vol. 12, no. 1, doi:10.1016/j.ymthe.2005.02.012, ISSN 1525-0016, pages 18 - 27, XP004925150
OPPOSITION- Sparwasser T., Et Al, "Bacterial DNA causes septic shock", Nature, (19970327), vol. 386, no. 6623, doi:10.1038/386336aO, pages 336 - 337, XP093127518
OPPOSITION- JURK et al., "Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound (Pub) R-848", Nature immunology, (20020600), vol. 3, no. 6, doi:10.1038/ni0602-499, page 499, XP009000821
OPPOSITION- Conroy H; Marshall N A; Mills K H G, "TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours", Oncogene, London , (20080107), vol. 27, no. 2, doi:10.1038/sj.onc.1210910, ISSN 0950-9232, pages 168 - 180, XP037742263
OPPOSITION- TOPALIAN et al., "Safety, Activity, and Immune correlates of Anti-PD-1 Antibody in cancer", N Eng J Med, (20120628), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, pages 2443 - 2454, XP055098235
OPPOSITION- SAUDER et al., "Randomized, Single-Blind, Placebo- Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults", Antimicrob. Agents Chemother., (20031200), vol. 47, no. 12, doi:10.1128/AAC.47.12.3846-3852.2003, pages 3846 - 3852, XP009078323
OPPOSITION- Stier Saskia, Maletzki Claudia, Klier Ulrike, Linnebacher Michael, "Combinations of TLR Ligands: A Promising Approach in Cancer Immunotherapy", CLINICAL & DEVELOPMENTAL IMMUNOLOGY, US , (20130101), vol. 2013, doi:10.1155/2013/271246, ISSN 1740-2522, pages 1 - 14, XP093004966
OPPOSITION- Bourquin Carole, Hotz Christian, Noerenberg Daniel, Voelkl Andreas, Heidegger Simon, Roetzer Laurin C., Storch Bettina, Sandholzer Nadja, Wurzenberger Cornelia, Anz David, Endres Stefan, "Systemic Cancer Therapy with a Small Molecule Agonist of Toll-like Receptor 7 Can Be Improved by Circumventing TLR Tolerance", Cancer research, US, (20110801), vol. 71, no. 15, doi:10.1158/0008-5472.CAN-10-3903, ISSN 0008-5472, pages 5123 - 5133, XP093004960
OPPOSITION- J. Fu, I.-J. Malm, D. K. Kadayakkara, H. Levitsky, D. Pardoll, Y. J. Kim, "Preclinical Evidence That PD1 Blockade Cooperates with Cancer Vaccine TEGVAX to Elicit Regression of Established Tumors", Cancer research, (20140801), vol. 74, no. 15, doi:10.1158/0008-5472.CAN-13-2685, ISSN 00085472, pages 4042 - 4052, XP055166598
OPPOSITION- RIBAS et al., "The future of cancertherapy: Selecting patients likely to respond to PD-1/L1 blockade", Clin Cancer Res, (20141001), vol. 20, no. 19, doi:10.1158/1078-0432.CCR-14-0933, pages 4982 - 4984, XP055259780
OPPOSITION- Nishii Naoto, Yuta Kondo, Lixin Li, Walter Lau, Hiroyuki Harada, And Miyuki Azuma, "Abstract 563: Combined treatment with PD-L1 blockade and a TLR7/8 agonist dramatically enhances antitumor immunity", Cancer Research, doi:10.1158/1538-7445.AM2016-563, (20160601), URL: http://cancerres.aacrjournals.org/content/76/14_Supplement/563, XP055575087
OPPOSITION- HEEREN et al., "High and Interrelated Rates of PD- L1+ CD 14+ Antigen-Presenting Cells and Regulatory T Cells Mark the Microenvironment of Metastatic Lymph Nodes from Patients with Cervical Cancer", CANCER IMMUNOLOGY RESEARCH, (20150106), vol. 3, no. 1, pages 288 - 295, XP009503020
OPPOSITION- Krieg Arthur M., "Development of TLR9 agonists for cancer therapy", The Journal of Clinical Investigation, B M J Group, (20070501), vol. 117, no. 5, doi:10.1172/JCI31414, pages 1184 - 1194, XP009155276
OPPOSITION- SMITS et al., "The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy", The Oncologist, (20080813), vol. 13, doi:10.1634/theoncologist.2008-0097, pages 859 - 875, XP055185106
OPPOSITION- HAILING LU, "TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects", Front. Immunol., (20140303), vol. 83, doi:10.3389/fimmu.2014.00083, pages 1 - 4, XP055382589
OPPOSITION- M. Singh, H. Khong, Z. Dai, X.-F. Huang, J. A. Wargo, Z. A. Cooper, J. P. Vasilakos, P. Hwu, W. W. Overwijk, "Effective Innate and Adaptive Antimelanoma Immunity through Localized TLR7/8 Activation", The Journal of Immunology, US , (20141101), vol. 193, no. 9, doi:10.4049/jimmunol.1401160, ISSN 0022-1767, pages 4722 - 4731, XP055290072
OPPOSITION- Hornung Veit et al, "Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides", The Journal of Immunology, Williams & Wilkins Co., US, US , (20020501), vol. 168, no. 9, doi:10.4049/jimmunol.168.9.4531, ISSN 0022-1767, pages 4531 - 4537, XP093127528
OPPOSITION- A. Forsbach et al, "Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses", The Journal of Immunology, Williams & Wilkins Co., US, US , (20080315), vol. 180, no. 6, doi:10.4049/jimmunol.180.6.3729, ISSN 0022-1767, pages 3729 - 3738, XP055244494
OPPOSITION- STATHOPOULOS et al., "Development of immune memory to glial brain tumors after tumor regression induced by immunotherapeuticToll-like receptor 7/8 activation", Oncoimmunology, (20120501), vol. 1, no. 3, doi:10.4161/onci.19068, pages 298 - 305, XP055974788
SEARCH- "Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies", CANCER IMMUNOLOGY RESEARCH, (20150301), vol. 3, no. 3, pages 288 - 295, XP009503020 [PX] 1-15 * page 291, column 1, paragraph 2 - column 2, paragraph 2 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents